About
Keira is a PRC-qualified corporate lawyer who advises Chinese enterprises and international clients on a broad range of PRC corporate and commercial matters. Her practice focuses on mergers and acquisitions, PRC inbound and outbound investment, private equity and venture capital transactions, and capital markets, with an emphasis on assisting clients executing deals efficiently while navigating PRC regulatory and compliance requirements.
With extensive experience at a leading “Red Circle” PRC law firm, Keira has advised on significant PRC and international M&A transactions, supporting Hong Kong and A-share listed companies with equity acquisitions in PRC targets, and guiding international investors through the complexities of China's foreign investment regime. She has particular expertise in advising on key PRC regulatory issues, including foreign exchange supervision, foreign investment restrictions and assisting clients navigating investment structures and compliance requirements.
Keira also advises PRC clients on various commercial matters, including leading complex reorganisations and restructurings of PRC-based groups, advising state-owned enterprises on regulatory approval procedures, and counselling clients on corporate governance structuring.
Keira’s expertise also covers general PRC corporate matters, such as joint ventures, licensing in/out transactions, employee share option plans, and corporate governance structuring – enabling her to provide seamless support across the full lifecycle of investment and expansion.
Keira speaks fluent English and Putonghua.
Experience
- Advised an A-share listed company on its RMB 541 million purchase of majority of equity interest in a PRC medical consumables company as part of their pipeline expansion.
- Assisted a Hong Kong listed company on its RMB 166 million acquisition of a Grade-A tertiary hospital in Xi’an, China.
- Advised a Hong Kong listed company on its acquisition of 100% equity interest of a PRC target in rare-earth and advanced materials industry.
- Advised an A-share listed company on its purchase of majority of equity interest in a PRC medical technology company as their strategic investor.
- Advised a Hong Kong listed company on its acquisition of a TCR biotech company in Beijing, China.
- Advised a leading global investment bank on its RMB 200 million and US$20 million Series C investment and convertible bond investment in a leading paediatric hospital group in Shanghai, China.
- Advised two leading venture capital firms on their US$25 million Series A investment in a leading online education platform in the PRC.
- Represented an innovative medical technology company in Nanjing, China, on its RMB 120 million Series B financing, led by a major pharmaceutical company's venture capital arm and a leading healthcare-focused investment fund.
- Advised a reputable venture capital firm on its Series A investment in an innovative medical technology company in Nanjing, China.
- Acted as the PRC legal counsel to a leading online recruitment platform on its U.S. IPO, Hong Kong listing, and HKEX main board follow-on offering (raising US$288 million).
- Acted as the Sponsor’s PRC legal counsel for a leading digital consumer finance platform’s U.S. IPO, Hong Kong listing, and issuance of US$600 million convertible bonds.
